ClinicalTrials.gg
RecruitingNCT05995769PAP-AUDUpdated May 7, 2024

Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

A Phase 2 interventional study of Psilocybin in Alcohol Use Disorder and Alcoholism, sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-07.

Sponsored by University of Calgary · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
22 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing psilocybin in Alcoholism — 8 open to participants now, 13 under way, 1 of them phase 3. Psilocybin · Alcoholism.

Planned enrollment
3rd of 17
128 · median 62
Started
2024
with 3 others
Phase 2
16 of 17
7 open now
Primary completion
2027-10
later than 7 of 12 live
Registered
9th of 17
by date

Among the 17 studies testing psilocybin in Alcoholism, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2024, is one of 16 in phase 2, reaches primary completion later than 7 of the 12 other live ones, and was the 9th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

8 of the 17 studies testing psilocybin in Alcoholism are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 22 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing psilocybin in Alcoholism, or all of them as a file.
02

Study summary

The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD).

Read the detailed description

The primary objective of this study is to determine if psilocybin administered with a standardized psychotherapeutic intervention, motivational enhancement therapy (MET), can reduce heavy drinking in a patient population with an alcohol use disorder (AUD). Patients with an AUD will be randomly allocated to either a high dose (25mg; active treatment) or a low dose (1mg; active control) psilocybin arm. All participants will receive 5 sessions of MET, starting at 24hrs post-dosing. Heavy drinking will be assessed as percent heavy drinking days using the Time Line Follow Back (TLFB) at baseline and 1-, 4-, and 12-weeks post-dosing.

A total of 128 male and female patients between the ages of 22-65 with a moderate to severe AUD diagnosis will be recruited from the community. Participants will undergo a thorough screening procedure and eligible participants will be randomly allocated to the high (N=64) or low (N=64) psilocybin doses. All participants will complete a baseline session consisting of clinical, behavioral, and neuroimaging measures. Following the single dosing session, participants will complete 5 weekly MET sessions. Neuroimaging measures will be assessed again at 1-week post-doing. Clinical and behavioral outcomes will be measured at 1-, 4-, and 12-weeks post-dosing

03

Conditions studied

  • Alcohol Use Disorder
  • Alcoholism

Browse trials for

04

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets AUD criteria of at least moderate severity
  • Meets heavy drinking requirements (heavy drinking days, number of drinks) in past 30 days
  • Desire to decrease alcohol consumption
  • Limited lifetime hallucinogen use

Exclusion criteria

Exclusion Criteria:

  • Severe or moderate substance use disorder other than alcohol or nicotine in past 6 months
  • Diagnosis of schizophrenia, bipolar disorders or first-degree relative with diagnosis
  • Active suicidal ideation or serious attempt within past 3 years
  • Currently pregnant, nursing, or trying to become pregnant
  • Any notable abnormality on , physical exam, or routine medical blood laboratory test
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    High Dose (25mg)

    PEX010 (Oral Psilocybin), 25mg; single dose administered 24hrs prior to first of 5 weekly MET sessions

    Drug: Psilocybin

  • Active comparator
    Low dose (1mg)

    PEX010 (Oral Psilocybin), 1mg; single dose administered 24hrs prior to first of 5 weekly MET sessions

    Drug: Psilocybin

Interventions

  • Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing

    Also known as: magic mushrooms, PEX010

06

What researchers measure

Primary outcomes

  1. Heavy drinking

    Percent heavy drinking days (TLFB)

    Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing

Secondary outcomes

  1. Abstinence

    Days abstinent (TLFB)

    Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing

  2. Biomarkers of alcohol consumption

    Phosphatidylethanol (Peth)

    Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing

  3. Alcohol cue reactivity

    Alcohol urge questionnaire (AUQ)

    Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing

  4. Cognitive flexibility

    Berg Card Sorting Task

    Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing

  5. Depression

    The Montgomery-Åsberg Depression Rating Scale (MADRS)

    Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing

  6. Anxiety

    The General Anxiety Disorder 7 (GAD-7) scale

    Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing

  7. Quality of life

    The World Health Organization Quality of Life (WHOQOL) scale

    Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing

  8. Glutamate levels

    MR spectroscopy of glutamate levels in the anterior cingulate cortex

    Time frame: Change from baseline to 1-week post-dosing

  9. GABA levels

    MR spectroscopy of GABA levels in the anterior cingulate cortex

    Time frame: Change from baseline to 1-week post-dosing

  10. Resting state functional connectivity

    Time frame: Change from baseline to 1-week post-dosing

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Oct 2027, 42 months after the start.

Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 42 months is above that.

Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2023
First posted
Aug 16, 2023
StartActual
Mar 20, 2024
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2027
Last update
May 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05995769
Collaborators
Johns Hopkins University, University of Maryland, Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Aug 16, 2023
Start date
Mar 20, 2024
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
May 7, 2024

Study contacts

Kaitlin O'Grady
Contact
pactlab@ucalgary.ca
587-893-0257
Leah Mayo, PhD
principal investigator · University of Calgary

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion